Background: The conduct of multicenter pharmacokinetic (PK) analyses for long-established drugs entails specific problems, because samples have to be obtained within daily clinical practice. Practices for intravenous (IV) drug administration vary between hospitals, including the use of different infusion devices, the use of infusion line systems with different line volumes, and different priming and rinsing procedures.
INTRODUCTION
It is often assumed that the intravenous (IV) route of administration is an appropriate way to guarantee rapid and proper delivery of the intended drug dose. Nevertheless, even for IV administrations, there are a variety of factors that may influence the rate of continuous drug administration and the start and end time of administration and thus may have an influence on pharmacokinetic (PK) analyses. These factors include the type of infusion device used, the infusion line assembly, and procedures to fill and empty the infusion line with drug at the beginning and end of infusion.
Usually, pharmaceutical industry-sponsored PK trials are performed in specialized phase I units or on the ward under conditions in which all these factors are standardized. However, many situations exist in which PK data are collected after administration of the drug within the daily hospital routine. For example, in pediatrics, there still exist a large number of drugs that have been used off-label for many years and for which PK data need to be obtained during therapeutic administration.
Two main types of infusion systems, drop-counter pump driven systems with infusion bags (drop-counter) or syringedriven infusion systems (syringe system), are used for drug administration and the choice between the 2 is mostly based on availability and experience within individual hospitals. Furthermore, the length and volumes of infusion lines can vary greatly, which might influence start and end time of infusion. 1 Other factors that may influence concentration data in PK studies are differences in priming and rinsing procedures. In specialized phase I/II clinical trial units, priming and rinsing are mostly avoided by using infusion lines prefilled with drug to guarantee an immediate start to the infusion. Furthermore, the infusion bag or syringe is overfilled with drug so that the infusion can run until the required drug amount-determined by the flow rate of the system-is administered (overfill method). Afterward, the residual amount of drug in the bag/ syringe and infusion line is discarded. This is a technique that allows precise definition of start and end of infusion but involves wasting a large volume of drug solution, raises safety issues, and is thus difficult to transfer to clinical routine.
In the daily clinical routine, hospital policies dictate whether or not infusion lines are primed with drug at the beginning of infusion. The practice of priming is particularly difficult to harmonize with cytostatic and/or toxic drugs. Many centers have a policy not to prime the line with drug because of safety concerns for staff, whereas other centers prefer the advantage of shorter infusion times and thus prime the lines irrespective of safety issues. Furthermore, no standard exists for the rinsing procedure at the end of infusion. Rinsing can be performed until the drug is completely administered or it can be stopped and the amount of drug remaining in the line discarded.
All the aforementioned points have to be considered when planning a multicenter PK trial. However, little data exist on the impact of these issues on drug delivery and PK. IV drug delivery kinetics at the beginning (onset) and at the end (offset) of infusions for 2 different infusion systems at different flow rates were therefore investigated in vitro to determine their influence on PK data. Furthermore, as a basis to harmonize rinsing procedures at the end of infusions, the percentage of total drug dose remaining in the infusion line at the end of infusions was analyzed. Experiments were performed in vitro and in the setting of a postmarketing PK trial to include variability arising by routine practices.
MATERIALS AND METHODS

Experiments in the Laboratory Setting
Two different infusion systems, a drop-counter and a syringe system, were used. Infusion lines were assembled according to routine practice in the Department of Pediatric Oncology and Hematology at the University Children's Hospital Muenster. The syringe system was composed of a Perfusor secura FT syringe driver, an Original Perfusor-infusion tube, a Discofix-3-gang manifold provided by B. Braun and an Ambix Noncor Plus port needle from Fresenius Kabi. The drop-counter system was composed of an InfusomatÒfmS, a ProSet Original-Infusomat-infusion tube, a Discofix-3-gang manifold provided by B. Braun and an Ambix Noncor Plus port needle from Fresenius Kabi.
The dead space volumes of the infusion line from the syringe or bag to the cannula were measured in triplicate for both systems. The dead space volume of the syringe system was 8 mL. As the drip chamber can be filled with different amounts of fluid, the dead space volume of an infusion system with drop-counter is generally more variable. The dead space volume was therefore standardized to 32.5 mL by always filling the drip chamber up to the same mark.
For both systems, onset and offset delivery kinetics were investigated. For onset experiments, the infusion system was filled with NaCl 0.9 g/dL of solution. A bag or syringe with drug solution at the "initial drug concentration" was connected to the infusion line and, at time point zero, the infusion was started at different flow rates. For offset experiments, the system was prefilled with drug solution (at the "initial drug concentration"), whereas the bag or syringe contained NaCl 0.9 g/dL rinsing solution.
Experiments were conducted with 2 colored solutions; Trypan blue solution (TB), provided by Sigma-Aldrich Chemie GmbH, or doxorubicin solution (Doxo), provided by the pharmacy of the University Hospital Muenster (UKM).
For both infusion systems, different flow rates were tested: 50 and 200 mL/h for the drop-counter and 25 and 50 mL/h for the syringe system, respectively. Samples were collected from the cannula at predetermined intervals. For the drop-counter, the samples of 1 mL were taken every 5 minutes at 50 mL/h and every minute at 200 mL/h. For the syringe systems, at the flow rate of 25 mL/h, samples were taken every 2 minutes and at 50 mL/h sampling was performed every minute. Sample collection continued until the drug was undetectable by visual observation in the delivery solution. All experiments were performed in triplicate.
For analytical purposes, 100 mL of each of the collected samples were pipetted in a 96-well microtiter plate. Concentrations of the 2 test substances were determined by ultraviolet spectroscopy with the Multiskan Ascent, Thermo Labsystems, with a 570-nm filter for TB and a 492-nm filter for Doxo. The method was validated with regard to accuracy and precision, and control samples were applied on each microtiter plate to ensure reliable results. The linear calibration range for TB was 5-300 mg/L and for Doxo 10-150 and 150-1000 mg/L. Mean values of the concentrations of the repeated measurements were plotted against time.
Onset Drug Delivery Kinetics
For the drop-counter flow rates of 50 and 200 mL/h and for the syringe system, a flow rate of 25 mL/h was used. This difference in the flow rates reflects the difference in clinical practice, where for drop-counters usually a larger volume and a higher flow rate is used than for syringe systems.
To characterize the curves, onset t conc 5% and onset t conc 100% values were defined as the times when 5% or 100% of the "initial drug concentration" was reached at the cannula. The difference between both values was calculated and represents the length of the concentration gradient in the line.
Furthermore, the "calculated onset time" was determined by dividing dead space volume by flow rate.
Offset Drug Delivery Kinetics
For offset experiments, offset t conc 95% and offset t conc 0% values were calculated. Those were the times when the drug concentration at the cannula dropped to 95% of the initial drug concentration or below the detection limit, respectively. The differences between these 2 values represent the length of the concentration gradient in the line.
Furthermore, the "calculated offset time" was determined, which ideally should be identical to the "calculated onset time." . Administration of 50 mg of Doxo over 2 hours, assuming that the infusion line was prefilled with drug solution at the beginning of infusion, was simulated for the following 3 infusion settings:
Influence of Drug
Simulation 1: 50 mg of Doxo given over 2 hours (overfill method).
Simulation 2: 50 mg of Doxo given over 2 hours with a drop-counter system at a flow rate of 50 mL/h. Simulation 3: 50 mg of Doxo given over 2 hours with a syringe system at a flow rate of 25 mL/h.
For simulations 2 and 3, it was assumed that rinsing was started immediately when the infusion alarm went on. The resulting decremental change in Doxo administration rates during the rinsing process was incorporated in Kinetica. They were determined as follows:
For the "initial drug concentration" against time curves obtained from the previous experiments, the areas under the curve (AUCs) were calculated using the linear trapezoidal rule. These "whole" AUCs were set equal to the amount of drug in the completely drug filled line, which was determined from dosage and line volume. Furthermore, "partial" AUCs for the same curves were calculated for consecutive 5-or 2-minute time intervals for the drop-counter or syringe system, respectively. The partial AUCs were set into relation to the "whole" AUCs and the amount of drug in the line to determine the amount of drug administered in each time interval.
Percentage of Total Drug Dosage Discarded After Different Rinsing Volumes
Based on the results of the offset-kinetic experiments described above, the amounts of drug discarded after different rinsing times were calculated as follows. First, for the "initial drug concentration" against time curve of the different offset-kinetic experiments, the AUC was calculated using the linear trapezoidal rule. This "whole" AUC was set equal to the amount of drug in a completely drug filled line. To determine the amount of drug remaining in the line after different rinsing periods, partial AUCs from time zero up to a time corresponding to passage of 1, 1.1, 1.2, 1.3, 1.5, and 2 dead space volumes of rinsing were calculated and set into relation to the "whole" AUCs and the amount of drug in the line. The calculated values were the amounts of drug remaining in the line as percentage of the drug amount in a drug filled line. Second, to obtain the percentage of total dosage to be administered, we assumed total drug volumes of 50, 100, or 200 mL and set the calculated values in relation.
Experiments in the Clinical Setting Percentage of Total Drug Dosage Discarded at the End of a Standardized Infusion
The amount of drug discarded at the end of a standardized infusion was measured within the CasLamb trial, a randomized multicenter phase II clinical trial to analyze the safety and PK of Caspofungin (CAS), liposomal Amphothericin B (LAMB) and the combination of both in allogenic hematopoetic stem-cell recipients. 3, 4 The study was performed in 5 German trial centers. Adult allogeneic hematopoietic stem-cell recipients (n = 55) with granulocytopenia and refractory fever received CAS, LAMB, or the combination of both until cessation of fever and granulocyte recovery. Embedded in this phase II clinical trial, in one of the participating centers (UKM), the solutions remaining in the infusion line at the end of infusions were collected and sent to the laboratory for drug analysis.
CAS and LAMB were given according to a standard operating procedure (SOP) defined in the trial study protocol: CAS and LAMB were administered as a 1-hour infusion using a drop-counter infusion system with a volume of the infusion line of 30 mL. Before the start of the infusion, the infusion line was prefilled with drug solution. The start time of infusion was exactly documented and the infusion was run at 260 mL/h. When the infusion bag was empty (after about 50 minutes), the bag was immediately changed to NaCl 0.9 g/ dL (CAS) or 5 g/dL dextrose (LAMB) and the infusion device was restarted at the same flow rate for exactly 10 minutes to administer drug remaining in the infusion line. In these circumstances, 10 minutes corresponded to rinsing with about 1.3 times the volume of the infusion line system. The time of the end of infusion was documented, and the solution remaining in the infusion system was transferred into a 50-mL tube and frozen at 2808C. Volume and drug concentrations of CAS and total amphotericin B were measured by validated highperformance liquid chromatography methods described in detail elsewhere. 3, 4 
RESULTS
Experiments in the Laboratory Setting
To determine the kinetics of drug delivery during onset and offset of the infusion, 2 substances, TB and Doxo, were used. Because the 2 tested substances showed comparable results, no distinction was made in all experiments, and both are referred to as "drug."
Onset Drug Delivery Kinetics
For the drop-counter, when starting the infusion, the drug solution dropped into the priming solution in the drip chamber and both liquids mixed continuously before entering the infusion line. This created a large drug concentration gradient in the line. In contrast, for the syringe system, in approximately one-third of the experimental runs an air bubble appeared when connecting the syringe (containing the drug) to the saline-filled infusion line. This led to a clear separation between the 2 solutions, and thus, the start of drug administration could be determined very precisely. In the remaining experimental runs the 2 liquids mixed at the transition making it more difficult to determine the exact start of drug administration. The results presented in Figure 1 contain only the latter runs and thus underestimate the advantage of the syringe system in determining the exact start time of infusion.
For the drop-counter flow rates of 50 and 200 mL/h and for the syringe system, a flow rate of 25 mL/h was used. As expected, there was a substantial lag time in the appearance of the drug at the cannula (onset t conc 5% ). This time was equal to 22 ± 0.5, 5.7 ± 0.3, and 16.5 ± 0.6 minutes (mean ± SD) for the 3 settings, respectively. The lag time until drug at the "initial drug concentration" (onset t conc 100% ) reached the cannula were determined as 70.0 ± 5.0, 15.3 ± 1.0, and 28.0 ± 2.0 minutes (mean ± SD), respectively.
The interval between the 2 times (onset t conc 5% and onset t conc 100% ) represents the concentration gradient in the line derived from mixing of the 2 solutions. The length of the gradient varied from close to 0 to 48 minutes, depending on the infusion system and the flow rates used. The largest interval of 48 minutes occurred for the drop-counter system at the lower flow rate of 50 mL/h. For the system at the higher flow rate, and for the syringe system with a flow rate of 25 mL/h, the concentration gradients were shorter, 9.6 and 11.5 minutes, respectively.
Furthermore, the theoretical times to the start of drug administration (calculated onset time) were determined from flow rate and dead space volume (39.0, 9.8, and 19.2 minutes for the 3 settings, respectively). This time always lay somewhere between onset t conc 5% and onset t conc 100% . Thus, for systems where longer concentration gradients arose, the calculated onset time was neither an accurate reflection of the time the first drug reached the patient, nor of the time steadystate administration was reached.
Offset Drug Delivery Kinetics
In analogy to the experiments on onset drug delivery kinetics, in vitro experiments to simulate the cessation of drug delivery during the rinsing process were performed (Fig. 2) .
Similar to the processes at the start of infusion, for the syringe-driven system, in one-third of all experimental runs an air bubble appeared, clearly separating both solutions in the infusion line. For Figure 2 , those data were removed from the data set.
The mean lag times until concentration started to drop at the cannula site of the infusion line (offset t conc 95% ) were 28.2 ± 1.2 and 6.1 ± 0.5 minutes (mean ± SD) for the drop-counter system with flow rates of 50 and 200 mL/h and 17.4 ± 1.6 and 7.7 ± 0.2 minutes (mean ± SD) for the syringe system with flow rates of 25 and 50 mL/h, respectively. For both infusion systems, the lag times correlated well with the flow rates.
The mean duration of the concentration gradients in the infusion line varied widely, 41.8 and 8.9 minutes (dropcounter with 50 and 200 mL/h) compared with 14.6 and 10.3 minutes (syringe system with 25 and 50 mL/h), making it impossible to exactly determine the end of infusion. For the drop-counter system, the length of this interval correlated directly to the flow rate, that is, the interval increased by roughly a factor of 4 when the infusion rate was decreased from 200 to 50 mL/h. However, this was not the case for the syringe system for which, when the flow rate was halved the interval increased only by a factor of 1.5. This suggested that lower flow rates create more mixing, which is a larger problem for the drop-counter than for the syringe system. Furthermore, the "calculated offset time" for the 4 settings [39 minutes/9.8 minutes (drop-counter with 50/200 mL/h), 19.2 minutes/9.6 minutes (syringe system with 25/50 mL/h)] was determined and compared with the actual end of infusion determined in the in vitro experiments. Similar to the situation with the start of infusion, this theoretical time was somewhere between offset t conc 95% and offset t conc 0% . Therefore, especially for systems where longer concentration gradients are projected, direct calculation is not a good determinant of either the time the drug concentration starts to decline, nor of the time until all drug is infused. 
Influence of Drug Administration Technique on the Plasma Concentration-Time Profile of the Drug
To determine the effect of varying infusion settings with their different offset kinetics on Doxo plasma concentrations 3 types of infusion settings were simulated with the PK-software program Kinetica. The administration of 50 mg of Doxo over 2 hours was simulated for (1) an infusion using the "overfill method," (2) administration using a drop-counter with a flow rate of 50 mL/h, and (3) administration using a syringe system with a flow rate of 25 mL/h.
As shown in Figure 3 , plasma drug concentrations differed only slightly for the 3 simulations in a time period from 110 to 150 minutes after start of infusion. The decline in drug concentration started soonest for simulation 2, followed by simulation 3, at approximately 10 and 4 minutes, respectively, before that observed in simulation 1. The prolonged administration of drug corresponded to a slower decline of estimated blood drug level for simulations 2 and 3.
These simulations demonstrated that the observations made during the in vitro experiments had a direct impact on Doxo blood concentrations. However, the estimated differences in blood concentrations were small and would not significantly affect PK analyses. Nevertheless, for peak drug concentrations (C max ) at the end of infusion, the measured concentration after infusion with a drop-counter system (simulation 2) would be approximately 30% lower relative to simulation 1.
Percentage of Total Drug Dosage Discarded After Different Rinsing Volumes
To evaluate suitable rinsing conditions, the relative amount of drug discarded at the end of infusion was investigated in vitro when rinsing was performed for 1-2 dead space volumes at the same flow rate as the infusion was administered.
The results of these experiments are shown for the drop-counter and the syringe system at 2 flow rates and 2 dosage volumes each (Fig. 4) . After rinsing for one dead space volume, the remaining amount of drug was ,5% for most settings. The higher the flow rate and the drug volume, the smaller was the percentage of drug remaining in the line. However, rinsing for one dead space volume was not enough when administering very small drug volumes with the syringe system. Here, approximately 10% of the total drug dose remained in the line.
After rinsing for 1.3 dead space volumes, the total drug dosage discarded was ,2% for all the chosen settings. If rinsing was expanded to 2 dead space volumes, no remaining drug was found in the lines.
Experiments in the Clinical Setting Percentage of Total Drug Dosage Discarded at the End of a Standardized Infusion
In addition, the amount of drug discarded at the end of a standardized infusion was investigated within a postmarketing PK trial of the antifungal compounds CAS and LAMB. Both compounds were administered with a drop-counter system over 1 hour, followed by rinsing at the end of infusion for 10 minutes, equal to 1.3 dead space volumes in the system used.
Samples from the infusion lines after rinsing were obtained for 103 CAS and 114 LAMB infusions (Fig. 5) . The mean drug amounts detectable in the infusion lines were 0.53% and 0.39% (range 0-6.31 and 0.01-3.31) of the calculated target dosage of CAS and LAMB, respectively.
DISCUSSION
The existence of potential pitfalls when performing therapeutic drug monitoring or PK analyses for IV administered drugs is not new. The first to report inconsistencies between expected and observed blood drug levels and to relate them to IV administration techniques were Roberts and Gould 5 and Nahata et al. 6 Both reports demonstrated lower than predicted peak or higher than predicted trough serum concentrations for different medicines administered to small children and infants. The authors proposed the site of drug insertion into the infusion system and thus the path that the drug had to traverse as one underlying factor.
Later several publications dealt with different potential difficulties regarding IV drug administration in the clinical setting. Many of these, like those of Roberts and Gould and Nahata, came from pediatric medicine, especially from neonatal intensive care or from surgery. In both cases, clinicians have to deal with situations that are more prone to administration failure. In pediatric patients, the smaller body weight of infants FIGURE 3. Experimentally determined offset delivery kinetics ( Figure 2 ) were used to simulate doxorubicin plasma concentration-time profiles for different infusion settings. A 2-hour infusion of 50 mg of doxorubicin was simulated in all cases. The continuous line shows the decline in doxorubicin plasma concentration if the infusion was abruptly stopped after 2 hours (simulation 1). The dotted and the dashed lines represent infusions with rinsing at the end of infusion, taking into account the slow offset drug delivery kinetics determined for the drop-counter at 50 mL/h (simulation 2) or the syringe system at 25 mL/h (simulation 3), respectively. The arrows indicate the time of the infusion-device alarm at which infusion was either stopped (simulation 1) or the rinsing process was started (simulations 2 and 3).
and neonates requires a restrictive fluid management and thus concurrent medications and fluids are often administered at slow flow rates. In contrast, in the operating room highly predictable and rapidly titratable drug administration is needed for infusions of sedative, analgesic, vasoactive, antiarrhythmic, or inotropic drugs. However, little has been published on the impact of IV administration technique on drug delivery and PK. Moreover, no official guidelines have been developed by the European Medicines Agency or Food and Drug Administration for handling IV drug infusions during clinical trials.
To clarify the necessary working procedures (WPs) for a multicenter, multinational trial to assess the PKs of Doxo in children and infants, the onset and offset infusion kinetics of 2 different infusion systems were studied. As expected, large differences in onset drug delivery kinetics for different infusion situations were determined when the infusion line was not prefilled with drug solution. Large time differences occurred between the time the first drug reached the patient, the time steady-state administration was reached and the calculated time until drug traversed the dead space volume of the line (calculated onset time). Comparable results were achieved when looking at drug delivery at the end of infusions. For both situations, time differences between calculated and real drug administration were more pronounced for slow infusion rates and for the drop-counter in comparison to the syringe system. With clearly specified infusion settings and good documentation only small differences in blood drug concentrations were seen after simulating the administration of Doxo with different offset infusion settings. However, if the documentation of infusion settings and times is not defined unambiguously, larger mistakes can occur with the drop-counter than with the syringe system.
Because during clinical routine research nurses are not always available to monitor start and end of infusions and to document administration times correctly, in a PK trial or for therapeutic drug monitoring the use of a standardized syringe system with low-volume infusion lines is preferred because it allows fewer possibilities for mistakes. Even so, special attention should be given to flow rate. The slower the flow rate, the more important is the reduction of the dead space volume of the infusion line. These observations are in agreement with recommendations by Roberts for the ideal IV drug administration system for pediatric patients that often face the problems of slow infusion rates. Roberts also recommended the use of low-volume IV tubing and overall small dead space volume in these situations. 7 To save time, some institutions raise the infusion rate until the drug reaches the patient at the beginning of infusions. However, from our experiments, it is obvious that the drug reaches the patient end of the infusion line, albeit at lower concentration, much earlier than predicted by simple calculation. Thus, when priming the line with drug is not possible, raising the flow rate while priming the line would reduce the overall infusion time, but could lead to administration of higher drug concentrations than anticipated. This could affect PK analysis or even present a risk of drug toxicity for the patient.
The same issue arises at the end of infusion. Here, when the infusion alarm starts, the infusion line is still completely filled with drug solution so that raising the flow rate would inevitably lead to an effective bolus drug administration and may result in toxicity. This was exemplified by the report of a girl with acute myeloid leukemia who developed a punctate keratitis of both eyes after high dose cytarabine therapy. This drug toxicity correlated with raised cytarabine plasma levels to twice the steady-state level at the end of infusion, which could be explained by a raised infusion rate during the rinsing process. 8 To create a basis for harmonizing rinsing procedures at the end of infusions, the minimum time of rinsing needed to administer the intended drug dose was determined. In vitro analyses showed that for the drop-counter rinsing for 1 dead space volume was sufficient, if up to 5% of the dose could be discarded. When rinsing for 1.3 dead space volumes ,2% of dosage was discarded. It should be noted that slow infusion rates were not investigated, but it is to be expected that the amount of drug remaining in the line would be higher for very slow infusions. For the syringe system rinsing needs to be done for at least 1.3 dead space volumes, especially when a low volume of drug is to be administered, because here .10% of dosage remained in the line after rinsing with only 1 dead space volume. This could be explained in part by a start-up delay of the syringe system as reported previously with a resulting delay in drug administration. 9, 10 Furthermore, because the concentration gradient in the infusion line of the syringe system is usually very short, a short delay might result in higher concentrations remaining in the line at that time. These investigations are in agreement with studies from Anh et al. who investigated drug loss during IV infusions to premature neonates. The authors suggested that the infusion line be flushed with 2 line volumes, because in their in vitro experiments rinsing for only 1 dead volume resulted in a loss of drug ranging from 1% to 44% for different drugs and settings. The higher loss of drug observed in contrast to our results can be explained by the small dosage volumes and slow flow rates used. 11 In addition, caution has to be exercised with drugs that adsorb strongly to plastic surfaces. Longer rinsing periods are supposedly required for those drugs. When setting up a clinical trial these factors need to be investigated before writing the respective WP.
Finally, to test if the in vitro results could be transferred into clinical practice, the amount of drug discarded at the end of a standardized infusion in the clinical setting was investigated. In this setting the same drop-counter system was used for all patients. Corresponding to the in vitro experiments, the amounts of drug discarded were ,1% of the dose in 90% of the cases. Only a few outliers were observed, with drug amounts up to 3.5% and 1 extreme outlier with 6% of total drug dosage left in the infusion line. The latter case is likely to be due to deviations from the SOP, but this cannot be proved because deviations from the SOP were not documented by the hospital staff in that trial. From this study, one can deduce that in a PK trial it would be helpful to reduce variability as much as possible and to clearly specify the infusion setting in a WP or SOP. The hospital staff should be trained to adhere to the SOPs as much possible and record any deviations to match outlier patient results to preclinical errors.
CONCLUSIONS
Large differences in drug delivery kinetics were detected at the beginning and end of infusions for different infusion settings. Calculation of the time during which drug traverses the infusion line and to define start or end of infusion proved to be imprecise. The time differences between calculated and real drug administration were more pronounced for slow infusion rates and the drop-counter in comparison with the syringe system.
With clearly specified infusion settings and good documentation, only small differences in blood drug concentrations were seen after simulating the administration of Doxo with different offset infusion settings. Conversely, if infusion settings and times are not defined unambiguously, larger mistakes can occur with the drop-counter than with the syringe system.
Regarding the optimal rinsing time at the end of infusion, the in vitro and clinical trial results presented here were in agreement and suggested that rinsing with 1.3 dead space volumes of the line was sufficient to administer .95% of the total drug dosage for most infusion settings.
Overall, one can conclude that the choice of the infusion apparatus, standardized infusion systems, and standardized operating procedures for drug administration are important when performing postmarketing PK analyses in multicenter studies.
